Insights into the post-translational modifications in heart failure
Xudong Zhang1, Yan Wang1, Huaping Li1
1Division of Cardiology, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, 1095# Jiefang Ave, Wuhan 430030, China; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.
Ageing Research Reviews
|August 26, 2024
Summary
Post-translational modifications (PTMs) like phosphorylation and acetylation play a key role in heart failure (HF) progression. Understanding these PTMs in different cardiac cells offers new therapeutic targets for HF.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biochemistry
Background:
- Heart failure (HF) is a major global health issue with a poor prognosis despite medical advances.
- HF involves complex subcellular dyssynchrony and detrimental remodeling of cardiac cells.
- Post-translational modifications (PTMs) are crucial regulators of protein function in cellular processes.
Purpose of the Study:
- To review the role of PTMs in the pathogenesis of different types of heart failure.
- To explore PTMs within specific subcellular locations and cell types relevant to HF.
- To identify potential therapeutic targets for HF based on PTM regulation.
Main Methods:
- Literature review focusing on PTMs in heart failure.
- Analysis of PTMs (phosphorylation, acetylation, ubiquitination, glycosylation) in distinct cardiac cell types and organelles.
- Examination of key proteins and signaling pathways affected by PTMs in HF.
Main Results:
- PTMs are integral to the detrimental remodeling observed in heart failure.
- Specific PTMs like phosphorylation, acetylation, ubiquitination, and glycosylation are implicated in HF progression.
- PTMs regulate key proteins and signaling sites within cardiomyocytes, fibroblasts, endothelial cells, and macrophages.
Conclusions:
- PTMs are critical regulators of cardiac function and dysfunction in heart failure.
- Targeting PTMs presents a promising avenue for novel therapeutic strategies in HF treatment.
- Further research into PTMs in specific HF contexts can lead to personalized treatment approaches.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Protein Modifications in the RER
5.1K
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
5.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
02:04Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:22Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324